128 related articles for article (PubMed ID: 10551410)
1. Syndecan-1 expression is diminished in acantholytic cutaneous squamous cell carcinoma.
Bayer-Garner IB; Sanderson RD; Smoller BR
J Cutan Pathol; 1999 Sep; 26(8):386-90. PubMed ID: 10551410
[TBL] [Abstract][Full Text] [Related]
2. The expression of syndecan-1 is preferentially reduced compared with that of E-cadherin in acantholytic squamous cell carcinoma.
Bayer-Garner IB; Smoller BR
J Cutan Pathol; 2001 Feb; 28(2):83-9. PubMed ID: 11168756
[TBL] [Abstract][Full Text] [Related]
3. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma.
Mukunyadzi P; Sanderson RD; Fan CY; Smoller BR
Mod Pathol; 2002 Jan; 15(1):45-9. PubMed ID: 11796840
[TBL] [Abstract][Full Text] [Related]
4. Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinoma.
Bayer-Garner IB; Dilday B; Sanderson RD; Smoller BR
Am J Dermatopathol; 2000 Apr; 22(2):119-22. PubMed ID: 10770430
[TBL] [Abstract][Full Text] [Related]
5. Decreased expression of intercellular adhesion molecules in acantholytic squamous cell carcinoma compared with invasive well-differentiated squamous cell carcinoma of the skin.
Griffin JR; Wriston CC; Peters MS; Lehman JS
Am J Clin Pathol; 2013 Apr; 139(4):442-7. PubMed ID: 23525614
[TBL] [Abstract][Full Text] [Related]
6. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma.
Mukunyadzi P; Liu K; Hanna EY; Suen JY; Fan CY
Mod Pathol; 2003 Aug; 16(8):796-801. PubMed ID: 12920224
[TBL] [Abstract][Full Text] [Related]
7. Reduction of syndecan-1 expression is associated with dysplastic oral epithelium.
Soukka T; Pohjola J; Inki P; Happonen RP
J Oral Pathol Med; 2000 Aug; 29(7):308-13. PubMed ID: 10947246
[TBL] [Abstract][Full Text] [Related]
8. Changes of cell adhesion and extracellular matrix (ECM) components in cervical intraepithelial neoplasia.
Sobel G; Szabó I; Páska C; Kiss A; Kovalszky I; Kádár A; Paulin F; Schaff Z
Pathol Oncol Res; 2005; 11(1):26-31. PubMed ID: 15800679
[TBL] [Abstract][Full Text] [Related]
9. Immunolabeling pattern of syndecan-1 expression may distinguish pagetoid Bowen's disease, extramammary Paget's disease, and pagetoid malignant melanoma in situ.
Bayer-Garner IB; Reed JA
J Cutan Pathol; 2004 Feb; 31(2):169-73. PubMed ID: 14690462
[TBL] [Abstract][Full Text] [Related]
10. Dermatofibroma: upregulation of syndecan-1 expression in mesenchymal tissue.
Sellheyer K; Smoller BR
Am J Dermatopathol; 2003 Oct; 25(5):392-8. PubMed ID: 14501288
[TBL] [Abstract][Full Text] [Related]
11. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas.
Mikami S; Ohashi K; Usui Y; Nemoto T; Katsube K; Yanagishita M; Nakajima M; Nakamura K; Koike M
Jpn J Cancer Res; 2001 Oct; 92(10):1062-73. PubMed ID: 11676857
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical localization of syndecan in mouse skin tumors induced by UV irradiation. Loss of expression associated with malignant transformation.
Inki P; Stenbäck F; Talve L; Jalkanen M
Am J Pathol; 1991 Dec; 139(6):1333-40. PubMed ID: 1750507
[TBL] [Abstract][Full Text] [Related]
13. The role of syndecan-1 in malignancies.
Inki P; Jalkanen M
Ann Med; 1996 Feb; 28(1):63-7. PubMed ID: 8932508
[TBL] [Abstract][Full Text] [Related]
14. Acantholysis and spongiosis are associated with loss of syndecan-1 expression.
Bayer-Garner I; Dilday B; Sanderson R; Smoller B
J Cutan Pathol; 2001 Mar; 28(3):135-9. PubMed ID: 11168765
[TBL] [Abstract][Full Text] [Related]
15. Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation.
Ito Y; Yoshida H; Nakano K; Takamura Y; Miya A; Kobayashi K; Yokozawa T; Matsuzuka F; Matsuura N; Kuma K; Miyauchi A
Histopathology; 2003 Aug; 43(2):157-64. PubMed ID: 12877731
[TBL] [Abstract][Full Text] [Related]
16. Syndecan-1 expression in laryngeal cancer.
Klatka J
Eur Arch Otorhinolaryngol; 2002 Mar; 259(3):115-8. PubMed ID: 12003262
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical localization of syndecan-1 in normal and pathological human uterine cervix.
Inki P; Stenbäck F; Grenman S; Jalkanen M
J Pathol; 1994 Apr; 172(4):349-55. PubMed ID: 8207616
[TBL] [Abstract][Full Text] [Related]
18. Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: participation of nuclear factor-kappaB in upregulation of syndecan-1 expression.
Watanabe A; Mabuchi T; Satoh E; Furuya K; Zhang L; Maeda S; Naganuma H
J Neurooncol; 2006 Mar; 77(1):25-32. PubMed ID: 16132527
[TBL] [Abstract][Full Text] [Related]
19. Altered proliferative and metastatic potential associated with increased expression of syndecan-1.
Hirabayashi K; Numa F; Suminami Y; Murakami A; Murakami T; Kato H
Tumour Biol; 1998; 19(6):454-63. PubMed ID: 9817973
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma.
Harada K; Masuda S; Hirano M; Nakanuma Y
Hum Pathol; 2003 Sep; 34(9):857-63. PubMed ID: 14562280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
